---
title: "Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist"
date: "2025-02-12 21:34:30"
summary: "Tivic Health Systems :TIVIC HEALTH ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO PHASE III TLR5 AGONIST FROM STATERA BIOPHARMATIVIC HEALTH SYSTEMS INC - TO PAY STATERA $1.2 MILLION IN EQUITY AND $300,000 CASH FOR ENTOLIMOD"
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Tivic Health Systems :

* TIVIC HEALTH ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO PHASE III TLR5 AGONIST FROM STATERA BIOPHARMA
* TIVIC HEALTH SYSTEMS INC - TO PAY STATERA $1.2 MILLION IN EQUITY AND $300,000 CASH FOR ENTOLIMOD

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_TUA9GMVZK:0-tivic-health-acquires-exclusive-worldwide-rights-to-phase-iii-tlr5-agonist/)
